Marc Frahm analyst TD COWEN

Currently out of the existing stock ratings of Marc Frahm, 4 are a BUY (40%), 6 are a HOLD (60%).

Marc Frahm

Work Performance Price Targets & Ratings Chart

Analyst Marc Frahm, currently employed at TD COWEN, carries an average stock price target met ratio of 50% that have a potential upside of 6.43% achieved within 48 days. Previously, Marc Frahm worked at COWEN.

Marc Frahm’s has documented 20 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TBPH, Theravance Biopharma at 06-Aug-2024.

Wall Street Analyst Marc Frahm

Analyst best performing recommendations are on TBPH (THERAVANCE BIOPHARMA).
The best stock recommendation documented was for TBPH (THERAVANCE BIOPHARMA) at 9/15/2021. The price target of $8 was fulfilled within 23 days with a profit of $1.23 (18.17%) receiving and performance score of 7.9.

Average potential price target upside

TBPH Theravance Biopharma IMGO Imago Biosciences DAWN Day One Biopharmaceuticals INCY yte XLO Xilio Development

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$15

$6.9 (85.19%)

$15

19 days ago

3/14 (21.43%)

$6.88 (84.73%)

35

Hold

$9

$0.9 (11.11%)

$10

1 months 29 days ago

3/6 (50%)

$1.17 (14.94%)

96

Buy

$10

$1.9 (23.46%)

$14

1 months 29 days ago

0/3 (0%)

$2.17 (27.71%)

Sell

$10

$1.9 (23.46%)

$10

2 years 2 months 10 days ago

2/8 (25%)

$0.76 (8.23%)

70

Buy

$12

$3.9 (48.15%)

$10

2 years 4 months 12 days ago

3/8 (37.5%)

$2.6 (27.66%)

85

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Marc Frahm is most bullish on?

Potential upside of $12.51 has been obtained for INCY (YTE)

Which stock is Marc Frahm is most reserved on?

Potential downside of $0.9 has been obtained for TBPH (THERAVANCE BIOPHARMA)

What Year was the first public recommendation made by Marc Frahm?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?